Pharmacokinetics and pharmacodynamics of cannabinoids.
Grotenhermen F.
Clin Pharmacokinet. 2003;42(4):327-60. doi: 10.2165/00003088-200342040-00003.
Cannabis: A Toxin-Producing Plant with Potential Therapeutic Uses.
Breijyeh Z, Jubeh B, Bufo SA, Karaman R, Scrano L.
Toxins (Basel). 2021 Feb 5;13(2):117. doi: 10.3390/toxins13020117.
[Addictions].
Karila L, Benyamina A.
Rev Mal Respir. 2019 Feb;36(2):233-240. doi: 10.1016/j.rmr.2018.12.001. Epub 2019 Jan 24.
Cannabinoids for Substance Use Disorder Treatment: What Does the Current Evidence Say?
Fernandes JAB, Filev R, Fidalgo TM.
Cannabis Cannabinoid Res. 2023 Oct;8(5):703-715. doi: 10.1089/can.2023.0065. Epub 2023 Jun 1.
Cannabinoids: emerging evidence in use and abuse.
Williams MV.
Emerg Med Pract. 2018 Aug;20(8):1-20. Epub 2018 Aug 1.
Synthetic Cannabinoids.
Mills B, Yepes A, Nugent K.
Am J Med Sci. 2015 Jul;350(1):59-62. doi: 10.1097/MAJ.0000000000000466.
Cannabidiol and addiction.
Briânis RC, Moreira FA, Iglesias LP.
Int Rev Neurobiol. 2024;177:319-333. doi: 10.1016/bs.irn.2024.03.006. Epub 2024 Jul 3.
The Synthetic Cannabinoids Phenomenon.
Karila L, Benyamina A, Blecha L, Cottencin O, Billieux J.
Curr Pharm Des. 2016;22(42):6420-6425. doi: 10.2174/1381612822666160919093450.
Cannabinoids for the treatment of cannabis use disorder: New avenues for reaching and helping youth?
Rømer Thomsen K, Thylstrup B, Kenyon EA, Lees R, Baandrup L, Feldstein Ewing SW, Freeman TP.
Neurosci Biobehav Rev. 2022 Jan;132:169-180. doi: 10.1016/j.neubiorev.2021.11.033. Epub 2021 Nov 22.
Drug addiction.
Justinova Z, Panlilio LV, Goldberg SR.
Curr Top Behav Neurosci. 2009;1:309-46. doi: 10.1007/978-3-540-88955-7_13.
